Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Change in Receivables (2016 - 2025)

Dexcom (DXCM) has disclosed Change in Receivables for 16 consecutive years, with $106.2 million as the latest value for Q4 2025.

  • Quarterly Change in Receivables rose 1335.14% to $106.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $201.9 million through Dec 2025, up 476.86% year-over-year, with the annual reading at $201.9 million for FY2025, 476.86% up from the prior year.
  • Change in Receivables for Q4 2025 was $106.2 million at Dexcom, up from -$237.8 million in the prior quarter.
  • The five-year high for Change in Receivables was $187.2 million in Q4 2023, with the low at -$237.8 million in Q3 2025.
  • Average Change in Receivables over 5 years is $38.6 million, with a median of $32.9 million recorded in 2021.
  • Peak annual rise in Change in Receivables hit 2467.24% in 2025, while the deepest fall reached 527.7% in 2025.
  • Over 5 years, Change in Receivables stood at -$15.1 million in 2021, then skyrocketed by 1082.12% to $148.3 million in 2022, then grew by 26.23% to $187.2 million in 2023, then crashed by 96.05% to $7.4 million in 2024, then surged by 1335.14% to $106.2 million in 2025.
  • According to Business Quant data, Change in Receivables over the past three periods came in at $106.2 million, -$237.8 million, and $184.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.